Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Immunotherapy achieves breakthrough result in patients with Hodgkin lymphoma

  • Margaret Shipp, MD

    A therapy that liberates the immune system to attack cancer cells drove Hodgkin lymphoma (HL) into complete or partial remission in fully 87 percent of patients with resistant forms of the disease who participated in an early-phase clinical trial, investigators at Dana-Farber Cancer Institute and partnering institutions report in a study published today in the New England Journal of Medicine and simultaneously presented at the annual meeting of the American Society of Hematology (ASH) in San Francisco.

    The results provide some of the most dramatic evidence to date of the potential of therapies that increase the ability of the immune system to kill cancer cells. While clinical trials of such immunotherapies in other cancers have shown them to be highly effective in a subgroup of patients, the new study stands out because nearly all patients benefited from the treatment.

    The success of the agent, nivolumab, in this study has prompted the U.S. Food and Drug Administration to designate it a "breakthrough therapy" for treating relapsed HL, and a large, multinational Phase 2 trial is now under way.

Posted on December 06, 2014

  • Margaret A. Shipp, MD
  • Immunotherapy
  • Hodgkin lymphoma
  • Media Contacts

    If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email media@dfci.harvard.edu.

    The Media Team cannot respond to patient inquiries. For more information, please see Contact Us.

  • New Patient Appointments

    For adults: 877-442-3324
    For children: 888-733-4662

    Make Appointment Online